Evidence map›Paper›PMID 33087513›Full record

ArticleMolecular cancer therapeutics2020

ASR490, a Small Molecule, Overrides Aberrant Expression of

Ashish Tyagi, Balaji Chandrasekaran, Venkatesh Kolluru, Becca V Baby, Cibi A Sripathi, Murali K Ankem, Srinivasa R Ramisetti, Venkat R Chirasani, Nikolay V Dokholyan, Arun K Sharma and 1 more

Open access · bronzeAbstract read
In one paragraph

Article in Molecular cancer therapeutics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.0field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Ashish TyagiDepartment of Urology, University of Louisville, Louisville, Kentucky.ORCID 0000-0003-2909-5755
Balaji ChandrasekaranDepartment of Urology, University of Louisville, Louisville, Kentucky.
Venkatesh KolluruDepartment of Urology, University of Louisville, Louisville, Kentucky.
Becca V BabyDepartment of Urology, University of Louisville, Louisville, Kentucky.
Cibi A SripathiDepartment of Urology, University of Louisville, Louisville, Kentucky.ORCID 0000-0003-3422-5737
Murali K AnkemDepartment of Urology, University of Louisville, Louisville, Kentucky.
Srinivasa R RamisettiDepartment of Pharmacology, Penn State Cancer Institute, Penn State College of Medicine, Hershey, Pennsylvania.
Venkat R ChirasaniDepartment of Pharmacology, Penn State Cancer Institute, Penn State College of Medicine, Hershey, Pennsylvania.
Nikolay V DokholyanDepartment of Pharmacology, Biochemistry and Molecular Biology, Penn State College of Medicine, Hershey, Pennsylvania.ORCID 0000-0002-8225-4025
Arun K SharmaDepartment of Pharmacology, Penn State Cancer Institute, Penn State College of Medicine, Hershey, Pennsylvania.
Chendil DamodaranDepartment of Urology, University of Louisville, Louisville, Kentucky. chendil.damodaran@louisville.edu.
University of Louisville · USPenn State Milton S. Hershey Medical Center · US

Funding

Penn State Clinical and Translational Science InstituteUL1TR002014 · NCATS · PENNSYLVANIA STATE UNIV HERSHEY MED CTR · PI KRASCHNEWSKI, JENNIFER L. · 2016 to 2025
$33.7M
University of Louisville Center for Integrative Environmental Health SciencesP30ES030283 · NIEHS · UNIVERSITY OF LOUISVILLE · PI Amanda Jo LeBlanc · 2020 to 2026
$10.0M
Nanoscale programming of cellular and physiological phenotypes: EquipmentR35GM134864 · NIGMS · UNIVERSITY OF VIRGINIA · PI Nikolay Dokholyan · 2020 to 2026
$5.2M
Chemoprevention of metastatic colorectal cancerR01CA185972 · NCI · UNIVERSITY OF LOUISVILLE · PI DAMODARAN, CHENDIL · 2014 to 2018
$2.0M
NCATS NIH HHS UL1 TR002014NCI NIH HHS R01 CA185972NIEHS NIH HHS P30 ES030283NIGMS NIH HHS R35 GM134864
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Antineoplastic AgentsBiomarkersCell Line, TumorColorectal NeoplasmsGene Expression Regulation, NeoplasticHCT116 CellsHumansReceptor, Notch1Receptor, Notch2Receptor, Notch3Antineoplastic AgentsBiomarkersNOTCH2 protein, humanNOTCH3 protein, humanReceptor, Notch1Receptor, Notch2Receptor, Notch3

Identifiers

PMID33087513
PMCPMC10694926
OpenAlexW3094342917

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.